KR101231856B1 - 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물 - Google Patents

생물학적 활성 화합물의 제어 방출 전달용 약학 조성물 Download PDF

Info

Publication number
KR101231856B1
KR101231856B1 KR1020077005752A KR20077005752A KR101231856B1 KR 101231856 B1 KR101231856 B1 KR 101231856B1 KR 1020077005752 A KR1020077005752 A KR 1020077005752A KR 20077005752 A KR20077005752 A KR 20077005752A KR 101231856 B1 KR101231856 B1 KR 101231856B1
Authority
KR
South Korea
Prior art keywords
biologically active
active compound
pharmaceutical composition
inositol
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077005752A
Other languages
English (en)
Korean (ko)
Other versions
KR20070043881A (ko
Inventor
리 유후아
벤자민 치엔
Original Assignee
큐피에스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큐피에스 엘엘씨 filed Critical 큐피에스 엘엘씨
Publication of KR20070043881A publication Critical patent/KR20070043881A/ko
Application granted granted Critical
Publication of KR101231856B1 publication Critical patent/KR101231856B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020077005752A 2004-08-12 2005-08-11 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물 Expired - Fee Related KR101231856B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60090704P 2004-08-12 2004-08-12
US60/600,907 2004-08-12
PCT/US2005/028676 WO2006017852A2 (en) 2004-08-12 2005-08-11 Pharmaceutical compositions for controlled release delivery of biologically active compounds

Publications (2)

Publication Number Publication Date
KR20070043881A KR20070043881A (ko) 2007-04-25
KR101231856B1 true KR101231856B1 (ko) 2013-02-08

Family

ID=35839986

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077005752A Expired - Fee Related KR101231856B1 (ko) 2004-08-12 2005-08-11 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물

Country Status (20)

Country Link
US (1) US7964219B2 (enExample)
EP (1) EP1786400B1 (enExample)
JP (1) JP5053846B2 (enExample)
KR (1) KR101231856B1 (enExample)
CN (1) CN101035512B (enExample)
AT (1) ATE424848T1 (enExample)
AU (1) AU2005271242B9 (enExample)
BR (1) BRPI0514297A (enExample)
CA (1) CA2576689C (enExample)
CY (1) CY1109425T1 (enExample)
DE (1) DE602005013244D1 (enExample)
DK (1) DK1786400T3 (enExample)
ES (1) ES2323141T3 (enExample)
MX (1) MX2007001760A (enExample)
NZ (1) NZ553149A (enExample)
PL (1) PL1786400T3 (enExample)
PT (1) PT1786400E (enExample)
RU (1) RU2390355C2 (enExample)
SI (1) SI1786400T1 (enExample)
WO (1) WO2006017852A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200009689A (ko) * 2018-07-19 2020-01-30 주식회사 아울바이오 주사제용 미립구의 제조방법

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005271242B9 (en) * 2004-08-12 2012-04-12 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions for controlled release delivery of biologically active compounds
ITRM20050344A1 (it) * 2005-06-30 2007-01-01 Luca Maria De Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
HRP20150186T1 (hr) 2005-08-19 2015-05-22 Amylin Pharmaceuticals, Llc. Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine
EP1968549B1 (en) * 2005-12-22 2014-05-14 Novartis AG Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
DK1984009T3 (da) * 2006-01-18 2013-01-28 Qps Llc Farmaceutiske sammensætninger med forbedret stabilitet
JP5189089B2 (ja) * 2006-06-22 2013-04-24 バイオコンパティブルズ ユーケー リミテッド 再水和可能な製薬製品
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
CN104000779A (zh) * 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
WO2009040019A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US8551072B2 (en) * 2007-12-12 2013-10-08 Boston Scientific Scimed, Inc. Methods, devices and compositions for controlled drug delivery to injured myocardium
US8497303B2 (en) * 2008-01-18 2013-07-30 Dow Global Technologies Llc Method to enhance aqueous solubility of poorly soluble actives
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
EP2213307A1 (en) * 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
MX347056B (es) * 2008-08-12 2017-04-10 Novartis Ag Composiciones farmaceuticas.
AU2009298411B2 (en) 2008-10-02 2013-06-06 Mylan Inc. Method of making a multilayer adhesive laminate
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
WO2010123563A2 (en) * 2009-04-23 2010-10-28 Sustained Nano Systems Llc Controlled release dispensing device
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
WO2011031996A2 (en) 2009-09-10 2011-03-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered microparticles for macromolecule delivery
DK2462246T3 (da) * 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
CN107412749A (zh) * 2010-02-22 2017-12-01 优势医疗公司 治疗脑的出血性病状的方法和组合物
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
KR101319420B1 (ko) * 2011-03-18 2013-10-17 한남대학교 산학협력단 서방형 방출이 가능한 수용성 양이온 약물 전달 시스템
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
CN102552169B (zh) * 2012-02-17 2015-07-29 深圳市健元医药科技有限公司 一种醋酸阿肽地尔缓释微球制剂及其制备方法
MY188825A (en) 2012-05-18 2022-01-06 Genentech Inc High-concentration monoclonal antibody formulations
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
US9040034B2 (en) 2013-04-09 2015-05-26 International Business Machines Corporation Vitamin functionalized gel-forming block copolymers for biomedical applications
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
CN103720663B (zh) * 2014-01-08 2016-04-06 昆药集团股份有限公司 一种促卵泡激素缓释微球及其制备方法
KR102533428B1 (ko) 2014-07-09 2023-05-16 피에르 파브르 메디카먼트 베피라돌을 이용한 이상운동질환 치료 방법
US11786469B2 (en) * 2014-07-22 2023-10-17 Cheolhee WON Silica nanoparticle composition for delivering bioactive material or protein such as a human proteasome
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
TWI694082B (zh) * 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
CA3036235A1 (en) 2016-09-09 2018-03-15 Irisys, Inc. Lipsomal anticancer compositions
EP4595970A3 (en) 2016-11-09 2025-10-29 Mayo Foundation for Medical Education and Research Manp analogues
DE102016013737A1 (de) * 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
EP3651800B1 (en) 2017-07-11 2024-04-10 Sustained Nano Systems LLC Hypercompressed pharmaceutical formulations
US10500163B2 (en) 2017-07-11 2019-12-10 Sustained Nano Systems Llc Radiation sterilization of hypercompressed polymer dosage forms
CA3112938C (en) * 2018-10-15 2023-08-15 Chong Kun Dang Pharmaceutical Corp. Injectable long-acting naltrexone microparticle compositions
AU2019375988A1 (en) 2018-11-09 2021-05-27 Mayo Foundation For Medical Education And Research Combination treatment for resistant hypertension
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CN112661958B (zh) * 2020-12-09 2023-03-17 中山大学 一种基于肌醇和精氨酸的聚酯酰胺及其制备方法与应用
WO2025054172A1 (en) 2023-09-05 2025-03-13 E-Star Biotech, LLC Formulations of manp and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0426630A (ja) * 1990-05-19 1992-01-29 Wakiyou Kagaku Kogyo Kk 水性製剤におけるリゾチーム塩の安定化方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824869A (en) * 1954-08-04 1958-02-25 Bristol Lab Inc Salt of streptomycin and phytic acid
US3242235A (en) * 1963-06-13 1966-03-22 Squibb & Sons Inc Phytate salts of the tetracyclines
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4578384A (en) * 1984-02-15 1986-03-25 The United States Of America As Represented By The Secretary Of The Army Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US6312679B1 (en) 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US4728202A (en) * 1987-01-14 1988-03-01 Emerson Electric Co. Shaft locking collar for bearing assemblies
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
DE4004430A1 (de) 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
WO1996021440A1 (en) * 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US5707970A (en) * 1997-02-12 1998-01-13 Nutrition 21 Arginine silicate complex and use thereof
US6410044B1 (en) 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6610702B2 (en) * 2000-08-01 2003-08-26 Gmp Oxycell, Inc. Ammonium salts of inositol hexaphosphate, and uses thereof
IL140017A (en) * 2000-11-30 2009-09-22 Abraham J Domb Polyhedra
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7226624B2 (en) * 2002-07-24 2007-06-05 Rabinowitz Israel N Synergistic compositions from yeast-modified aqueous extracts from almond hulls
AU2003262804A1 (en) * 2002-08-22 2004-03-11 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
AU2003286472A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
AU2005271242B9 (en) * 2004-08-12 2012-04-12 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions for controlled release delivery of biologically active compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0426630A (ja) * 1990-05-19 1992-01-29 Wakiyou Kagaku Kogyo Kk 水性製剤におけるリゾチーム塩の安定化方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200009689A (ko) * 2018-07-19 2020-01-30 주식회사 아울바이오 주사제용 미립구의 제조방법
KR102137786B1 (ko) 2018-07-19 2020-07-24 주식회사 아울바이오 주사제용 미립구의 제조방법

Also Published As

Publication number Publication date
DE602005013244D1 (de) 2009-04-23
JP5053846B2 (ja) 2012-10-24
CN101035512B (zh) 2012-01-18
ATE424848T1 (de) 2009-03-15
AU2005271242B2 (en) 2011-09-15
MX2007001760A (es) 2007-07-24
US20060034923A1 (en) 2006-02-16
ES2323141T3 (es) 2009-07-07
KR20070043881A (ko) 2007-04-25
DK1786400T3 (da) 2009-06-29
CA2576689C (en) 2012-10-09
EP1786400A2 (en) 2007-05-23
CN101035512A (zh) 2007-09-12
US7964219B2 (en) 2011-06-21
RU2007105872A (ru) 2008-09-20
EP1786400B1 (en) 2009-03-11
AU2005271242A2 (en) 2006-02-16
RU2390355C2 (ru) 2010-05-27
SI1786400T1 (sl) 2009-08-31
AU2005271242B9 (en) 2012-04-12
HK1108638A1 (en) 2008-05-16
CY1109425T1 (el) 2014-08-13
AU2005271242A1 (en) 2006-02-16
JP2008511544A (ja) 2008-04-17
NZ553149A (en) 2010-01-29
CA2576689A1 (en) 2006-02-16
PT1786400E (pt) 2009-06-19
WO2006017852A3 (en) 2006-08-31
BRPI0514297A (pt) 2008-06-10
PL1786400T3 (pl) 2009-08-31
WO2006017852A2 (en) 2006-02-16
EP1786400A4 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
KR101231856B1 (ko) 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물
KR101466933B1 (ko) 펩타이드의 지속 방출 전달을 위한 의약 조성물
US6465425B1 (en) Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
EP1984009B1 (en) Pharmaceutical compositions with enhanced stability
US5470582A (en) Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
EP2462896A1 (en) Method for the preparation of controlled release formulations
KR100486028B1 (ko) 단백질 함유 서방성 리피드 임플란트 및 이의 제조방법
HK1108638B (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
HK1131751B (en) Pharmaceutical compositions for sustained release delivery of peptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160104

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170102

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180201

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190116

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210205

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210205

P15-X000 Request for amendment of ip right document rejected

St.27 status event code: A-5-5-P10-P15-nap-X000